Citations

Mayo Clinic

Clear

662 citation(s) found for "Yu, Eugene".

B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival
Krambeck, Amy E. , Thompson, R. Houston, Lohse, Christine M. , Park, Eugene S., Kuntz, Susan M., Leibovich, Bradley C. , Blute, Michael L., Cheville, John C. , Kwon, Eugene D., Dong, Haidong

Proceedings of the National Academy of Sciences | June 23, 2006 | Volume: 103 | Issue: 27 | Pages: 10391-10396

10.1073/pnas.0600937103 | PMID 16798883 Get It

B7-H4 is a recently described B7 family coregulatory ligand that has been implicated as an inhibitor of T cell-mediated immunity. Although expression of B7-H4 is typically limited to lymphoid cells, aberrant B7-H4 expression has also been reported in several human malignancies. To date, associations of B7-H4 with clinical outcomes for cancer patients are lacking. Therefore, we examined B7-H4 expression in fresh-frozen tumor specimens from 259 renal cell carcinoma (RCC) patients treated with nephrectomy between 2000 and 2003 and performed correlative outcome analyses. We report that 153 (59.1%) RCC tumor specimens exhibited B7-H4 staining and that tumor cell B7-H4 expression was associated with adverse clinical and pathologic features, including constitutional symptoms, tumor necrosis, and advanced tumor size, stage, and grade. Patients with tumors expressing B7-H4 were also three times more likely to die from RCC compared with patients lacking B7-H4 (risk ratio = 3.05; 95% confidence interval = 1.51–6.14; P = 0.002). Additionally, 211 (81.5%) specimens exhibited tumor vasculature endothelial B7-H4 expression, whereas only 6.5% of normal adjacent renal tissue vessels exhibited endothelial B7-H4 staining. Based on these findings, we conclude that B7-H4 has the potential to be a useful prognostic marker for patients with RCC. In addition, B7-H4 represents a target for attacking tumor cells as well as tumor neovasculature to facilitate immunotherapeutic treatment of RCC tumors. Last, we demonstrate that patients with RCC tumors expressing both B7-H4 and B7-H1 are at an even greater risk of death from RCC.
A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk
Kanis, John А. , Johansson, Helena , Odén, Anders, Johnell, Olof, Laet, Chris De , Melton, L. Joseph, Tenenhouse, Alan, Reeve, J. , Pols, Huibert A. P., Eisman, John A. , McCloskey, Eugène , Cruz‐Jentoft, Alfonso J. , Silman, Alan J. , Mellström, Dan

Journal of Bone and Mineral Research | April 27, 2006 | Volume: 19 | Issue: 6 | Pages: 893-899

10.1359/jbmr.040134 | PMID 15125788 Get It

Abstract The relationship between use of corticosteroids and fracture risk was estimated in a meta-analysis of data from seven cohort studies of ∼42,000 men and women. Current and past use of corticosteroids was an important predictor of fracture risk that was independent of prior fracture and BMD. Introduction: The aims of this study were to validate that corticosteroid use is a significant risk factor for fracture in an international setting and to explore the effects of age and sex on this risk. Materials and Methods: We studied 42,500 men and women from seven prospectively studied cohorts followed for 176,000 patient-years. The cohorts comprised the EPOS/EVOS study, CaMos, the Rotterdam Study, Dubbo Osteoporosis Epidemiology Study (DOES), and prospective cohorts at Sheffield, Rochester, and Gothenburg. The effect of ever use of corticosteroids, BMD, age, and sex on all fracture, osteoporotic fracture, and hip fracture risk alone was examined using Poisson regression in each cohort and for each sex. The results of the different studies were merged from the weighted β coefficients. Results: Previous corticosteroid use was associated with a significantly increased risk of any fracture, osteoporotic fracture, and hip fracture when adjusted for BMD. Relative risk of any fracture ranged from 1.98 at the age of 50 years to 1.66 at the age of 85 years. For osteoporotic fracture, the range of relative risk was 2.63-1.71, and for hip fracture 4.42-2.48. The estimate of relative risk was higher at younger ages, but not significantly so. No significant difference in risk was seen between men and women. The risk was marginally and not significantly upwardly adjusted when BMD was excluded from the model. The risk was independent of prior fracture. In the three cohorts that documented current corticosteroid use, BMD was significantly reduced at the femoral neck, but fracture risk was still only partly explained by BMD. Conclusion: We conclude that prior and current exposure to corticosteroids confers an increased risk of fracture that is of substantial importance beyond that explained by the measurement of BMD. Its identification on an international basis validates the use of this risk factor in case-finding strategies.
Quantitative and Graphic Acoustic Analysis of Phonatory Modulations
Buder, Eugene H. , Strand, Edythe A.

Journal of Speech, Language, and Hearing Research | April 18, 2006 | Volume: 46 | Issue: 2 | Pages: 475-490

10.1044/1092-4388(2003/039) | PMID 14700387 Get It

A method is presented for analyzing phonatory instabilities that occur as modulations of fundamental frequency (f 0 ) and sound pressure level (SPL) on the order of 0.2 to 20 cycles per second. Such long-term phonatory instabilities, including but not limited to traditional notions of tremor, are distinct from cycle-to-cycle perturbation such as jitter or shimmer. For each of the 2 parameters (f 0 , in Hz, and SPL, in dB), 3 frequency domains are proposed: (a) flutter (10–20 Hz), (b) tremor (2–10 Hz), and (c) wow (0.2–2.0 Hz), yielding 6 types of instability. Analyses were implemented using fast Fourier transforms (FFTs) with domain-specific analysis parameters. Outputs include a graphic display in the form of a set of low-frequency spectrograms (the “modulogram”) and quantitative measures of the frequencies, magnitudes, durations, and sinusoidal form of the instabilities. An index of a given instability is developed by combining its duration and average modulation magnitude into a single quantity. Performance of the algorithms was assessed by analyzing test signals with known degrees of modulation, and a range of applications was reviewed to provide a rationale for use of modulograms in phonatory assessment.
Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up
Thompson, R. Houston, Kuntz, Susan M., Leibovich, Bradley C. , Dong, Haidong , Lohse, Christine M. , Webster, W. Scott, Sengupta, Shomik , Frank, Igor, Parker, Alexander S. , Zincke, Horst, Blute, Michael L., Sebo, Thomas J., Cheville, John C. , Kwon, Eugene D., Dong, Haidong

Cancer Research | April 3, 2006 | Volume: 66 | Issue: 7 | Pages: 3381-3385

10.1158/0008-5472.can-05-4303 | PMID 16585157 Get It

Abstract B7-H1 participates in T-cell costimulation functioning as a negative regulator of immunity. Recent observations suggest that B7-H1 is expressed by renal cell carcinoma (RCC) tumor cells and is associated with poor prognosis. However, outcome analyses have been restricted to patients with fresh-frozen tissue and limited follow-up. We report the clinical effect of B7-H1 in RCC patients with a median of 10 years of follow-up. Between 1990 and 1994, 306 patients underwent nephrectomy for clear cell RCC and had paraffin tissue available for review. We did immunohistochemistry with anti-B7-H1 and conducted outcome analyses. Among the 306 patients, 73 (23.9%) harbored tumors with B7-H1 expression. Patients with tumor B7-H1 were at a significantly increased risk of both death from RCC [risk ratio (RR), 3.92; P < 0.001] and overall mortality (RR, 2.37; P < 0.001). The 5-year cancer-specific survival rates were 41.9% and 82.9% for patients with and without tumor B7-H1, respectively. In a multivariate model, tumor B7-H1 remained associated with cancer-specific death even after adjusting for tumor-node-metastasis stage, grade, and performance status (RR, 2.00; P = 0.003). In the subset of 268 patients with localized RCC, tumor B7-H1 was significantly associated with metastatic cancer progression (RR, 3.46; P < 0.001) and death from RCC (RR, 4.13; P < 0.001) even after adjusting for stage, grade, and performance status (RR, 1.78, P = 0.036). RCC patients with tumor B7-H1 are at significant risk of rapid cancer progression and accelerated rates of mortality. B7-H1 may function as a key determinant in RCC, abrogating immune responses directed against this immunogenic tumor. (Cancer Res 2006; 66(7): 3381-5)
A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
Orth, James D. , Krueger, Eugene W. , Weller, Shaun G. , McNiven, Mark A.

Cancer Research | April 3, 2006 | Volume: 66 | Issue: 7 | Pages: 3603-3610

10.1158/0008-5472.can-05-2916 | PMID 16585185 Get It

Abstract Cells form transient, circular dorsal ruffles or “waves” in response to stimulation of receptor tyrosine kinases, including epidermal growth factor receptor (EGFR) or platelet-derived growth factor receptor. These dynamic structures progress inward on the dorsal surface and disappear, occurring concomitantly with a marked reorganization of F-actin. The cellular function of these structures is largely unknown. Here we show that EGF-induced waves selectively sequester and internalize ∼50% of ligand-bound EGFR from the cell surface. This process requires receptor phosphorylation, active phosphatidylinositol 3-kinase, and dynamin 2, although clathrin-coated pits or caveolae are not required. Epithelial and fibroblast cells stimulated with EGF sequestered EGFR rapidly into waves that subsequently generated numerous receptor-positive tubular-vesicular structures. Electron microscopy confirmed that waves formed along the dorsal membrane surface and extended numerous tubules into the cytoplasm. These findings characterize a structure that selectively sequesters large numbers of activated EGFR for their subsequent internalization, independent of traditional endocytic mechanisms such as clathrin pits or caveolae. (Cancer Res 2006; 66(7): 3603-10)
Prospective Study of Survival Outcomes in Non-Hodgkin's Lymphoma Patients With Rheumatoid Arthritis
Endo, Justin , Puumala, Susan E. , Aoun, Patricia, Black, Natalie A., O’Dell, James R., Stoner, Julie A., Boilesen, Eugene, Bast, Martin, Bergman, Debra, Ristow, Kay M., Ooi, Melissa , Mikuls, Ted R. , Armitage, Jamés O. , Habermann, Thomas M.

Journal of Clinical Oncology | March 7, 2006 | Volume: 24 | Issue: 10 | Pages: 1597-1602

10.1200/jco.2005.04.6227 | PMID 16520462 Get It

Purpose Although preliminary studies suggest that non-Hodgkin's lymphoma (NHL) complicating rheumatoid arthritis (RA) may be a clinically distinct entity compared with that occurring in the general population, studies examining the impact of antecedent RA on survival are limited. In this prospective study, we examined the association of RA with survival in patients with NHL. Patients and Methods Using two large lymphoma registries, we identified patients with evidence of RA preceding NHL. Survival in RA patients was compared with that of controls using proportional hazards regression, adjusting for the effects of age, sex, lymphoma diagnosis-to-treatment lag time, calendar year, International Prognostic Index score, and NHL grade. Results The frequency of NHL subtypes was similar in RA patients (n = 65) and controls (n = 1,530). Compared with controls, RA patients with NHL had similar overall survival (hazard ratio [HR] = 0.95; 95% CI, 0.70 to 1.30) but were at lower risk of lymphoma progression or relapse (HR = 0.41; 95% CI, 0.25 to 0.68) or death related to lymphoma or its treatment (HR = 0.60; 95% CI, 0.37 to 0.98), but were more than twice as likely to die from causes unrelated to lymphoma (HR = 2.16; 95% CI, 1.33 to 3.50). Conclusion RA is associated with improved NHL-related outcomes, including a 40% reduced risk of death occurring as a result of lymphoma or its treatment and approximately a 60% lower risk of lymphoma relapse or progression compared with non-RA controls. However, the survival advantage gained in RA from the acquisition of lymphomas with favorable prognoses is negated through an increased mortality from other comorbid conditions.
Rare Expression of KIT and Absence of KIT Mutations in High Grade Renal Cell Carcinoma
Sengupta, Shomik , Cheville, John C. , Corless, Christopher L. , Lohse, Christine M. , Heinrich, Michael C. , Kwon, Eugene D., Zincke, Horst, Blute, Michael L., Leibovich, Bradley C. , Heinrich, Michael C

Journal of Urology | December 22, 2005 | Volume: 175 | Issue: 1 | Pages: 53-56

10.1016/s0022-5347(05)00059-5 | PMID 16406868 Get It

Rupture of Canine Erythrocytes in Ultrasonic Fields in which Cavitation Has Been Suppressed
Ackerman, Eugene

The Journal of the Acoustical Society of America | November 9, 2005 | Volume: 35 | Issue: 5_Supplement | Pages: 809-809

10.1121/1.2142566 Get It

Canine blood was diluted with isotonic Rous-Turner solution at pH 5.8 or at 7.0. The suspended erythrocytes were exposed to ultrasonic energy at 495 kc/sec with cavitation either occurring or being suppressed by excess pressure. The same power was applied to the transducer whether or not cavitation was occurring. The rupture of the cells was measured spectrophotometrically. In addition, the osmotic fragility of the exposed cells was compared with that of control cells. The results were analyzed and graphed, using an IBM-1620 computer. These studies indicated that (1) canine erythrocytes can be ruptured in the absence of cavitation, albeit more slowly; (2) mechanical strength as determined ultrasonically is not simply related to osmotic fragility; (3) the changes of osmotic fragility after ultrasonic treatment were different from those after heating; (4) the destruction not due to cavitation occurred at intensities between those used for surgery and those used for physical therapy. [This work, performed with the technical assistance of N. Nolder, A. Hildestad, and L. C. Gatewood, was aided by National Institutes of Health grants GM 08299-02 and FR-00007.]
Prostate Cancer Immunology: Biology, Therapeutics, and Challenges
Webster, W. Scott, Kwon, Eugene D., Small, Eric J. , Rini, Brian I.

Journal of Clinical Oncology | November 8, 2005 | Volume: 23 | Issue: 32 | Pages: 8262-8269

10.1200/jco.2005.03.4595 | PMID 16278482 Get It

A number of recently developed and promising approaches to antitumoral immunotherapy are being investigated as potential treatments for advanced prostate cancer. These approaches largely revolve around strategies to increase antigen-specific T-cell activation against prostate tumors as well as precise manipulations of critical co-regulatory receptors that help to maintain and prolong the activity of antigen-presenting cells and T cells that are capable of mediating tumor regression. Herein, we describe the experience with the most recent and promising approaches pertaining to prostate cancer immunotherapy. Additionally, we discuss the mechanistic basis for these approaches as well as current limitations that must still be addressed in order to propel immunotherapy into the forefront of prostate cancer treatment.
A SCORING ALGORITHM TO PREDICT SURVIVAL FOR PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA: A STRATIFICATION TOOL FOR PROSPECTIVE CLINICAL TRIALS
Leibovich, Bradley C. , Cheville, John C. , Lohse, Christine M. , Zincke, Horst, Frank, Igor, Kwon, Eugene D., Blute, Michael L., Merchan, Jaime R.

Journal of Urology | October 7, 2005 | Volume: 174 | Issue: 5 | Pages: 1759-1763

10.1097/01.ju.0000177487.64651.3a | PMID 16217278 Get It